Profile data is unavailable for this security.
About the company
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
- Revenue in USD (TTM)11.65m
- Net income in USD-36.56m
- Incorporated2000
- Employees33.00
- LocationCuris Inc128 Spring Street, Building C, Suite 500LEXINGTON 02421United StatesUSA
- Phone+1 (302) 658-7581
- Fax+1 (302) 655-5049
- Websitehttps://www.curis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Traws Pharma Inc | 2.85m | 93.35m | 12.95m | 7.00 | 0.0574 | 2.54 | -- | 4.55 | 28.24 | 28.24 | 0.4566 | 0.6373 | 0.2662 | -- | 1.38 | 406,571.40 | -124.51 | -151.85 | -517.46 | -207.35 | -- | -- | -467.64 | -21,652.42 | -- | -- | 0.00 | -- | 0.00 | -36.47 | -188.55 | -- | -- | -- |
| Curanex Pharmaceuticals Inc | 0.00 | -1.30m | 13.26m | -- | -- | 0.928 | -- | -- | -0.0497 | -0.0497 | 0.00 | 0.5043 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -142.76 | 0.00 | -- | -- | -- | -1,782.87 | -- | -- | -- |
| BioCardia Inc | 0.00 | -8.54m | 14.33m | 17.00 | -- | 5.45 | -- | -- | -1.73 | -1.73 | 0.00 | 0.2476 | 0.00 | -- | -- | 0.00 | -137.58 | -102.48 | -272.63 | -150.23 | -- | -- | -- | -1,938.01 | -- | -- | 0.00 | -- | -87.84 | -39.41 | 31.33 | -- | -47.18 | -- |
| Cocrystal Pharma Inc | 0.00 | -9.67m | 14.47m | 11.00 | -- | 1.79 | -- | -- | -0.9356 | -0.9356 | 0.00 | 0.5881 | 0.00 | -- | -- | 0.00 | -72.50 | -43.29 | -83.33 | -45.24 | -- | -- | -- | -4,873.78 | -- | -- | 0.00 | -- | -- | -- | 2.67 | -- | -43.98 | -- |
| Curis Inc | 11.65m | -36.56m | 14.83m | 33.00 | -- | -- | -- | 1.27 | -3.68 | -3.68 | 1.05 | -1.15 | 0.3323 | -- | 3.75 | 353,030.30 | -104.28 | -37.70 | -259.56 | -42.63 | 99.47 | 96.89 | -313.79 | -423.79 | -- | -- | -- | -- | 8.83 | 1.75 | 8.49 | -- | -- | -- |
| Iterum Therapeutics PLC | 390.00k | -26.96m | 15.05m | 9.00 | -- | -- | -- | 38.59 | -0.7488 | -0.7488 | 0.0107 | -0.1507 | 0.0161 | -- | 0.9512 | 43,333.33 | -111.35 | -99.44 | -231.48 | -169.64 | 94.87 | -- | -6,913.08 | -- | 1.96 | -3.43 | 1.28 | -- | -- | -- | 35.44 | -- | -39.16 | -- |
| Bioatla Inc | 0.00 | -64.71m | 15.15m | 61.00 | -- | -- | -- | -- | -1.15 | -1.15 | 0.00 | -0.5313 | 0.00 | -- | -- | 0.00 | -165.61 | -49.22 | -317.99 | -57.35 | -- | -- | -- | -3,690.17 | -- | -- | -- | -- | -- | 16.17 | 43.48 | -- | -- | -- |
| NuCana PLC (ADR) | 0.00 | -36.89m | 15.42m | 20.00 | -- | 0.4436 | -- | -- | -7,083.74 | -7,083.74 | 0.00 | 4.85 | 0.00 | -- | -- | 0.00 | -106.16 | -47.75 | -180.13 | -58.87 | -- | -- | -- | -- | -- | -1.59 | 0.0052 | -- | -- | -- | 31.25 | -- | -25.32 | -- |
| P3 Health Partners Inc | 1.44bn | -131.05m | 15.56m | 360.00 | -- | -- | -- | 0.0108 | -40.18 | -40.18 | 442.85 | -5.72 | 1.91 | -- | 14.07 | 4,013,756.00 | -37.78 | -49.89 | -113.11 | -253.77 | -4.05 | -1.15 | -19.83 | -46.73 | -- | -5.36 | 0.9304 | -- | 18.48 | 59.38 | -135.14 | -- | -- | -- |
| Allarity Therapeutics Inc | 0.00 | -15.31m | 16.00m | 6.00 | -- | 1.33 | -- | -- | -2.31 | -2.31 | 0.00 | 0.7455 | 0.00 | -- | -- | 0.00 | -74.37 | -62.78 | -122.61 | -113.20 | -- | -- | -- | -- | -- | -- | 0.1037 | -- | -- | -- | -23.21 | -- | 106.17 | -- |
| Citius Pharmaceuticals Inc | 3.94m | -35.89m | 16.18m | 23.00 | -- | 0.2023 | -- | 4.10 | -2.92 | -2.92 | 0.2707 | 3.57 | 0.0302 | 0.0426 | -- | 171,483.00 | -29.76 | -29.86 | -48.25 | -35.19 | 79.99 | -- | -985.09 | -- | 0.4006 | -128.99 | 0.0106 | -- | -- | -- | 6.85 | -- | 400.55 | -- |
| IN8bio Inc | 0.00 | -20.66m | 16.60m | 18.00 | -- | 0.5915 | -- | -- | -6.48 | -6.48 | 0.00 | 2.87 | 0.00 | -- | -- | 0.00 | -126.22 | -79.60 | -150.81 | -91.19 | -- | -- | -- | -- | -- | -- | 0.0299 | -- | -- | -- | -1.43 | -- | -10.74 | -- |
| Regentis Biomaterials Ltd | 0.00 | -13.65m | 16.68m | -- | -- | 3.52 | -- | -- | -24.08 | -24.08 | 0.00 | 0.9159 | 0.00 | -- | -- | -- | -336.99 | -188.09 | -- | -- | -- | -- | -- | -- | -- | -1.02 | 0.2015 | -- | -- | -- | -360.91 | -- | -- | -- |
| Lixte Biotechnology Holdings Inc | 0.00 | -4.13m | 16.71m | 2.00 | -- | 7.09 | -- | -- | -1.18 | -1.18 | 0.00 | 0.8612 | 0.00 | -- | -- | 0.00 | -114.55 | -113.03 | -130.06 | -121.30 | -- | -- | -- | -- | -- | -1,017.39 | 0.00 | -- | -- | -- | 29.51 | -- | -- | -- |
Data as of Mar 03 2026. Currency figures normalised to Curis Inc's reporting currency: US Dollar USD
29.67%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Bleichroeder LPas of 31 Dec 2025 | 1.14m | 8.78% |
| Armistice Capital LLCas of 31 Dec 2025 | 883.58k | 6.83% |
| M28 Capital Management LPas of 23 Jan 2026 | 521.06k | 4.03% |
| CM Management LLCas of 31 Dec 2025 | 325.00k | 2.51% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 302.90k | 2.34% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 240.92k | 1.86% |
| Citigroup Global Markets, Inc. (Investment Management)as of 31 Dec 2025 | 176.84k | 1.37% |
| Geode Capital Management LLCas of 31 Dec 2025 | 101.33k | 0.78% |
| Squarepoint OPS LLCas of 31 Dec 2025 | 86.48k | 0.67% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 61.66k | 0.48% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
